LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
VTGN
VistaGen Therapeutics, Inc.
There isn't enough reported data to score VTGN yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
VTGN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
VTGN's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
VTGN PE Valuation
VTGN has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
VTGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect VTGN's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over VTGN on earnings quality, reporting a profit while its opponent remains loss making.
VTGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.66 | +$0.13 |
| Q1 2026 | -$1.83 | -$0.16 |
| Q4 2023 | -$3.53 | +$5.77 |
| Q3 2023 | -$4.81 | +$4.49 |
| Q2 2023 | -$6.55 | +$2.45 |
| Q1 2023 | -$8.61 | -$1.41 |
| Q4 2022 | -$9.30 | +$1.50 |
| Q3 2022 | -$9.30 | +$2.10 |
VTGN is still losing money, but far less than before: $1.66 per share over the past year, against $20.70 at its worst in late 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over VTGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over VTGN on profitability, with a higher operating margin.
VTGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1.5M | +505% |
| Q4 2025 | $303K | +29% |
| Q3 2025 | $258K | +41% |
| Q2 2025 | $244K | +190% |
| Q4 2024 | $234K | -43% |
| Q3 2024 | $183K | -34% |
| Q1 2024 | $197.3K | +12% |
| Q1 2023 | $176K | +351% |
VTGN's revenue has grown year over year for five quarters in a row: $1M last quarter, up 505% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -904% | +5573 points |
| Q1 2026 | -3595% | N/A |
| Q4 2025 | -6451% | +11 points |
| Q3 2025 | -7772% | +1.8 points |
| Q2 2025 | -6477% | +7965 points |
| Q4 2024 | -6462% | -4545 points |
| Q3 2024 | -7774% | -5333 points |
| Q2 2024 | -14442% | N/A |
VTGN's operating margin was −904% last quarter, up 5573 points from the same quarter a year ago, near the top of its range since 2020.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over VTGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
VTGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$14.7M | +$4.1M |
| Q1 2026 | -$16.2M | -$6.1M |
| Q4 2025 | -$17.6M | -$7.4M |
| Q3 2025 | -$13.8M | -$2.9M |
| Q2 2025 | -$18.8M | -$8M |
| Q4 2024 | -$10.3M | -$5.7M |
| Q3 2024 | -$10.9M | -$4.7M |
| Q2 2024 | -$10.9M | -$3M |
VTGN has burned cash in almost every quarter: −$62M over the past year, against −$50M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over VTGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
VTGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +4.9M shares |
| 1 year | +35% | +11M shares |
| 3 years | +500% | +35.8M shares |
| 5 years | +783% | +38.1M shares |
| Available history | +2925% | +41.6M shares |
VTGN has 43M diluted shares, up 35% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
VTGN Net Leverage
VTGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
VTGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 1.6 | Oversold |
VTGN's weekly RSI is 31 (neutral) and its Stochastic is 2 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
VTGN PE vs Healthcare Sector
VTGN has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over VTGN on trend strength, trading above more of its moving averages.
VTGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.21 | 14% below |
| 20 week MA | $0.23 | 22% below |
| 50 week MA | $0.61 | 70% below |
| 100 week MA | $1.79 | 90% below |
| 200 week MA | $2.90 | 94% below |
VTGN is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over VTGN on returns for 2026, with the stronger performance.
VTGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.0 | $41.7 | +99% |
| 2021 | $41.7 | $60.9 | +46% |
| 2022 | $60.9 | $3.00 | -95% |
| 2023 | $3.00 | $5.14 | +71% |
| 2024 | $5.14 | $2.57 | -50% |
| 2025 | $2.57 | $0.73 | -72% |
| 2026 YTD | $0.73 | $0.18 | -75% |
VTGN has finished lower in three of the last six years. It's down 75% so far in 2026.